Miles, D., de haas, S., Dirix, L., Romieu, G., Chan, A., Pivot, X., . . . Scherer, S. (2013). Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Nature Publishing Group.
Chicago Style (17th ed.) CitationMiles, D., et al. Biomarker Results from the AVADO Phase 3 Trial of First-line Bevacizumab Plus Docetaxel for HER2-negative Metastatic Breast Cancer. Nature Publishing Group, 2013.
MLA (9th ed.) CitationMiles, D., et al. Biomarker Results from the AVADO Phase 3 Trial of First-line Bevacizumab Plus Docetaxel for HER2-negative Metastatic Breast Cancer. Nature Publishing Group, 2013.
Warning: These citations may not always be 100% accurate.